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Abstract 
Background: Very little is known about the incidence and prevalence of hydrocephalus in patients with mucopoly-
saccharidoses (MPS). The biggest challenge is to distinguish communicating hydrocephalus from ventricular dilata-
tion secondary to brain atrophy, because both conditions share common clinical and neuroradiological features. The 
main purpose of this study is to assess the relationship between ventriculomegaly, brain and cerebrospinal fluid (CSF) 
volumes, aqueductal and cervical CSF flows, and CSF opening pressure in MPS patients, and to provide potential 
biomarkers for abnormal CSF circulation.
Methods: Forty-three MPS patients (12 MPS I, 15 MPS II, 5 MPS III, 9 MPS IV A and 2 MPS VI) performed clinical and 
developmental tests, and T1, T2, FLAIR and phase-contrast magnetic resonance imaging (MRI) followed by a lumbar 
puncture with the CSF opening pressure assessment. For the analysis of MRI variables, we measured the brain and 
CSF volumes, white matter (WM) lesion load, Evans’ index, third ventricle width, callosal angle, dilated perivascular 
spaces (PVS), craniocervical junction stenosis, aqueductal and cervical CSF stroke volumes, and CSF glycosaminogly-
cans concentration.
Results: All the scores used to assess the supratentorial ventricles enlargement and the ventricular CSF volume 
presented a moderate correlation with the aqueductal CSF stroke volume (ACSV). The CSF opening pressure did not 
correlate either with the three measures of ventriculomegaly, or the ventricular CSF volume, or with the ACSV. Dilated 
PVS showed a significant association with the ventriculomegaly, ventricular CSF volume and elevated ACSV.
Conclusions: In MPS patients ventriculomegaly is associated with a severe phenotype, increased cognitive decline, 
WM lesion severity and enlarged PVS. The authors have shown that there are associations between CSF flow measure-
ments and measurements related to CSF volumetrics. There was also an association of volumetric measurements with 
the degree of dilated PVS.
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Background
The mucopolysaccharidoses (MPS) are a group of rare 
genetic disorders of glycosaminoglycan (GAG) catabo-
lism. Each MPS disorder is caused by a deficiency in the 
activity of a single, specific lysosomal enzyme required 
for GAG degradation. Lysosomal accumulation of GAGs 
results in chronic and progressive cellular damage, which 
can affect multiple organ systems. The neurologic expres-
sion of the disease varies among the different MPS types 
and sometimes also within the same type [1]. Ventricular 
enlargement is known to occur in patients with MPS and 
may be due to the combination of cortical atrophy sec-
ondary to central nervous system degeneration, a defect 
in cerebrospinal fluid (CSF) reabsorption due to thicken-
ing of the meninges and dysfunction of the Pacchionian 
granulations in the arachnoid villi, and venous hyperten-
sion secondary to reduced venous outflow through bone 
dysostosis of the skull base [2, 3]. The communicating 
hydrocephalus that occurs in MPS is usually slowly pro-
gressive and difficult to distinguish from the primary 
neurologic disease. Acute symptoms such as vomit-
ing and papilledema are uncommon. The ventricular 
enlargement in severe forms of MPS I (Hurler syndrome) 
and MPS II (Hunter syndrome) may be associated with 
increased intracranial pressure (ICP), which can be used 
as indication for a shunting procedure. The degree to 
which hydrocephalus contributes to the neurologic dete-
rioration in MPS is unknown [1].
Because brain atrophy and communicating hydro-
cephalus share common clinical and neuroradiologi-
cal features in MPS patients, and in addition, they can 
potentially coexist, these two conditions were previously 
considered as one [4]. Ventriculomegaly is a cardinal fea-
ture of hydrocephalus and the severity can be defined by 
an Evans’ index greater than 0.3 [5]. Several authors used 
magnetic resonance imaging (MRI) scoring systems to 
grade the ventricular enlargement and help differentiate 
between hydrocephalus and ex vacuo ventriculomegaly 
in MPS patients, taking into account mainly the width 
of the third ventricle and temporal horn dilatation [2, 
6–9]. Measuring the callosal angle has been suggested 
as a convenient method for discriminating idiopathic 
normal pressure hydrocephalus (INPH) from neuro-
degenerative disease with large ventricles due to atro-
phy [10]. Excess build-up of CSF leads to an increase in 
ICP, which can be equated to CSF opening pressure. The 
relationship between size of cerebral ventricles and ICP 
has previously been investigated in adults and children 
with hydrocephalus, and conventional knowledge says 
that, with exception of some acute cases, brain imaging 
is rarely helpful in guessing value of ICP quantitatively 
[11–14]. We recently published an algorithm to aid in 
the diagnosis and management of hydrocephalus in MPS 
patients, considering neurologic deterioration, Evans’ 
index, width of the third ventricle, callosal angle, CSF 
opening pressure and the presence of craniocervical ste-
nosis [15].
At present, neuroimaging has only been only used to 
verify the extent of ventriculomegaly and exclude cases of 
gross cerebral atrophy and other pathological conditions 
that might explain the neurological deterioration in MPS 
patients. Phase-contrast (PC) MRI provides valuable 
additional information to conventional MRI and could 
help to distinguish hydrocephalus from brain atrophy in 
MPS patients by measuring the volume of CSF pulsat-
ing back and forth through the aqueduct with each car-
diac cycle, the aqueductal CSF stroke volume (ACSV). 
According to Bradley, hyperdynamic CSF flow through 
the aqueduct is seen when there is ventricular enlarge-
ment without cerebral atrophy [16]. However, while some 
studies have supported the use of aqueductal flow rate 
for the diagnosis of INPH [17, 18] and related flow rate 
to a possible shunt response [19, 20], other studies have 
not been able to demonstrate any association between a 
clinical improvement after shunting and increased ACSV 
[21–23] or flow rate [24].
Currently, there is a lack of consensus as to which diag-
nostic test most reliably predicts which MPS patients will 
benefit from CSF diversion. Moreover, it has proved to 
be very difficult, using any objective measure, to dem-
onstrate a neurological improvement after CSF drain-
age that could indicate an eventual positive response to 
ventriculoperitoneal shunting (VPS) [25]. There is also 
great difficulty in investigating these patients due to: rare 
disease, behavioral disturbances, high anesthetic risk, 
technical difficulties for lumbar puncture and low CSF 
drainage, for which invasive tests such as intermittent 
high volume spinal tap, prolonged lumbar drainage and 
continuous ICP monitoring are not feasible [15]. In this 
context, a noninvasive tool for selecting MPS patients 
with hydrocephalus for surgery would certainly be pref-
erable, if the evidence for its utility was convincing.
The purpose of this study was to provide images of both 
structural and quantitative changes in the brain allowing 
access to and a better understanding of the brain disease 
and the consequences of hydrocephalus in patients with 
MPS. In that sense, we aimed to be able to identify non-
invasive potential biomarkers for abnormal CSF circula-
tion. Besides that, we analyzed the relationship between 
ventricular and cervical CSF flows and ventricular size, 
brain and CSF volumes, CSF opening pressure, CSF 
GAGs levels, dilated  perivascular spaces (PVS), white 
matter (WM) lesion load, and craniocervical junction 
stenosis.
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Methods
Subjects
This was a cross-sectional study. From July 2013 to June 
2016, we examined all patients with MPS followed at the 
Medical Genetics Service of Hospital de Clínicas de Porto 
Alegre. Of these, 47 patients with confirmed biochemi-
cal diagnosis of MPS underwent evaluation for ventricu-
lomegaly. We excluded three subjects who had VPS and 
one who was unable to undergo the MRI due to respira-
tory compromise and clinical instability. The remaining 
43 patients formed the study group (12 patients with 
MPS I, 15 with MPS II, 5 with MPS III, 9 with MPS IV 
A, and 2 with MPS VI). Of the MPS I patients, 5 had 
Hurler syndrome, 2 had Hurler-Scheie syndrome and 5 
had Scheie syndrome. Of the MPS II patients, 8 had the 
severe form and 7 had the attenuated form. Of the MPS 
III patients, 1 had type A, 3 had type B and 1 had type C. 
Twenty-five patients were male and 18 were female. Each 
patient presented with typical clinical manifestations 
of the disorder and had biochemical confirmation of a 
deficient enzymatic activity (α-l-iduronidase for MPS I, 
iduronate sulfatase for MPS II, heparan N-sulfatase for 
MPS III A, α-N-acetyl-glucosaminidase for MPS III B, 
acetyl-CoA: α-glucosaminide acetyltransferase for MPS 
III C, galactose 6-sulfatase for MPS IVA, and N-acetylga-
lactosamine 4-sulfatase for MPS VI). Multiple sulfatase 
deficiency was excluded by the observation of a normal 
activity of at least one other sulfatase. Twenty patients 
were receiving enzyme replacement therapy (7 with MPS 
I, 10 with MPS II, 1 with MPS IV A and 2 with MPS VI). 
Each patient had brain MR imaging immediately fol-
lowed by lumbar puncture, and neurodevelopmental 
assessment performed within the same week, except one 
patient who died before intellectual test could be applied.
Neurodevelopmental assessment
All patients received age-appropriate standardized neu-
rodevelopmental assessments: Bayley Scales of Infant 
and Toddler Development Third Edition (Bayley-III) for 
children younger than 42  months, Wechsler Preschool 
and Primary Scale of Intelligence—Revised (WPPSI-R) 
for children between 42  months and 6  years, Wechsler 
Intelligence Scale for Children Third Edition (WISC-III) 
for patients between 6 and 16 years, and Wechsler Adult 
Intelligence Scale Third Edition (WAIS-III) for patients 
who were 16  years or older. All tests were performed 
according to their guidelines and to the developmen-
tal level of each patient by a psychologist (S.G.P.P.) who 
was experienced in development neurology. According 
to the study protocol, full-scale IQ scores were rated and 
patients presented as having cognitive impairment (CI) 
or not. CI was considered present when developmen-
tal tests (composite score) or intelligence quotient (IQ) 
<70. Severely affected patients who could not respond to 
development tests were classified within the CI group.
CSF sampling
Each patient underwent a lumbar puncture in a flexed 
lateral decubitus position whereby 7–10  cc of CSF was 
removed. The CSF opening pressure was measured with 
a standard spinal manometer calibrated in mm  H2O 
(Hako, Germany) connected to a 20-G spinal needle. In 
five patients, it was not possible to obtain the opening 
pressure or the CSF sample due to technical difficulties 
(3 patients) or refusal to undergo the procedure after per-
forming MRI (2 patients).
Data acquisition
MRI studies were obtained on 1.5T Achieva (Philips Medi-
cal Systems, Best, The Netherlands) software version 2.6.3. 
For the acquisition of the cerebral images and the cervical 
region we used a 16-channel neurovascular coil manufac-
tured by Invivo Devices. The research protocol for brain 
images included fast spin echo transversal plane FLAIR 
(TR 11000  ms; TE 140  ms; IT 2800  ms; flip 90°; NSA 3; 
slice thickness 5 mm; gap 1 mm; matrix 169 × 225; in plane 
resolution 1.3 × 1.03 mm; echo train length 55); fast spin 
echo transversal plane T2 (5054 ms; 100 ms; 90°; 2; 5 mm; 
1  mm; 219  ×  292; 0.75  ×  0.59; 15); MPRAGE sagittal 
plane T1 (8.69 ms; 4 ms; 8°; 1 mm; 232 × 256; 1 × 1 mm; 
232); cervical spine included fast spin echo T2 sagittal 
plane (4735 ms; 100 ms; 90°; 4; 3 mm; 0.5 mm; 247 × 198; 
1 × 0.9 mm; 24); fast spin echo T2 axial plane (3800 ms; 
120 ms; 90°; 4; 3 mm; 0.4 mm; 247 × 198; 1.11 × 0.85 mm; 
44); fast spin echo T1 sagittal plane (958 ms; 7.8 ms; 90°; 
3; 3 mm; 0.5 mm; 247 × 198; 1.25 × 0.9 mm; 4); through-
out plane flow was measured with PC gradient echo for 
CSF at aqueduct and cervical subarachnoid space at C2–
C3 spine level with velocity encoding (Venc) equal to 
12 cm/s (TR 21 ms; TE 12 ms; flip 10°; NSA 2; slice thick-
ness 5 mm; no gap; matrix 182 × 182; in plane resolution 
0.55 × 0.55 mm) and 10 cm/s (21 ms; 12 ms; 10°; 2; 5 mm; 
220 × 182; 0.55 × 0.5 mm), respectively. For those patients 
whose CSF flow was very distinct, the Venc was adjusted 
accordingly to reduce flow void artifacts and achieve 
higher image contrast.
Imaging processing
Neuroimage post-processing was performed at a work-
station by three researchers in agreement (A.D.C., M.A. 
and F.K.M.). They were blinded to the age, type, and clini-
cal status of the patients.
Lesion load, CSF and brain volumes
Cerebral segmentation and WM lesion load were meas-
ured with FLAIR brain images and CSF with T2-weighted 
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images. The segmentation process and volume quantifi-
cation were performed as described in detail elsewhere 
[26] to obtain brain volume, total CSF volume, ventricu-
lar CSF volume, subarachnoid CSF volume and lesion 
load. The skull size was used as denominator to correct 
brain and CSF volumes for variations in head size.
Size of the supratentorial ventricles
Evans’ index was calculated as the ratio of the greatest 
width of the frontal horns of the lateral ventricles to the 
maximal internal diameter of the skull [5]. The third 
ventricle enlargement was graded as follows: 1 = width 
of the third ventricle <5  mm; 2  =  width of the third 
ventricle between 5 and 10 mm; 3 = width of the third 
ventricle >10 mm [9]. The callosal angle was measured 
on the coronal plane, which was perpendicular to the 
anteroposterior commissure plane on the posterior 
commissure of each subject [10]. The Evans’ index, the 
width of third ventricle and the corpus callosal angle 
were calculated on the individual MPRAGE sagittal T1 
reoriented to the parallel plane from the anteroposte-
rior commissure plane consisting of 1.0-mm isotropic 
voxels. Ventriculomegaly was defined as Evans’ index 
>0.3, width of the third ventricle >10  mm, or callosal 
angle <90°.
Enlargement of the perivascular spaces
The PVS enlargement on T1-weighted images located 
in periventricular and subcortical WM, corpus callo-
sum, basal ganglia, thalami and brainstem, were graded 
as follows: 0 = none; 1 = PVS number <10 and PVS size 
<3  mm; 2  =  PVS number ≥10 and PVS size <3  mm; 
3 = PVS number ≥10 and PVS size ≥3 mm [9].
Craniocervical junction stenosis
For MRI evaluation of the craniocervical junction, sag-
ittal and axial T1- and T2-weighted images were cre-
ated. The T2-weighted images were also examined for 
increased signal intensity, suggesting myelomalacia. The 
presence or absence of a compression of the spinal cord 
was graded as follows: 0 = no spinal cord compression; 
1  =  spinal cord compression (absence of CSF in any 
direction); 2 = signs of myelomalacia [27].
Aqueductal and cervical CSF stroke volume
Stroke volumes were defined as the average of cranio-
caudal and caudocranial volumes displaced through the 
region of interest (ROI) during the cardiac cycle (CC) 
[28]. They were measured for CSF in the aqueduct and 
cervical level and were expressed in milliliters per CC. 
Data were analyzed using validated image processing 
software [29] with an optimized CSF flow segmenta-
tion algorithm, which automatically extracts the ROI at 
each level, and calculates its flow curves over the 32 seg-
ments of the CC. Then, the CSF flow curve was generated 
within one CC (Figs. 1, 2). High CSF stroke volume was 
defined as aqueductal >0.05 ml/CC and C2–C3 >0.5 ml/
CC [30].
CSF GAGs analysis
Total CSF GAGs concentration was determined using a 
thrombin activity assay. The CSF samples were preincu-
bated with human heparin cofactor II (HC II) and then 
incubated with a fixed amount of thrombin and with 
0.5 mmol/l chromogenic substrate S-2238 in assay buffer. 
The quantification of the GAG concentrations was per-
formed as described elsewhere [31].
Fig. 1 Data acquisition of a 34-year-old male patient with MPS II. Sagittal 3D scout view sequences were used as localizer to select the anatomical 
levels for flow quantification (a). The acquisition planes were selected perpendicular to the presumed direction of the flows. Sections through the 
cerebral aqueduct (b) and C2–C3 subarachnoid space level (c) were used for CSF flow measurement
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Statistical analysis
Continuous variables were described using median and 
range, due to asymmetric distributions. Categorical data 
were presented as counts and percentages. Comparison 
of groups was conducted using Mann–Whitney U test 
or Fisher exact test, accordingly. To evaluate correla-
tions between continuous and ordinal variables we used 
Spearman’s rank correlation coefficient  (rs). Due to mul-
tiple comparisons, all p values in Table  1 were adjusted 
using Finner’s adjustment procedure. Additionally, odds 
ratios were computed to estimate magnitude of asso-
ciation between categorical data. In situations where the 
odds ratio was undefined using traditional methods we 
approximated using Peto odds ratio.
Selected continuous measurements with no prior 
defined cut-off points were dichotomised using median 
values which are presented in Table 2. Therefore, adopted 
cut-off values were: CSF protein level >32  mg/dl, CSF 
GAGs >250 ng/ml, PVS ≥10; WM lesion load >0.4 cm3; 
ACSV >0.05 ml/CC; C2–C3 CSF stroke volume >0.5 ml/
CC.
The significance level was set at p  <  0.05. Data were 
analysed using IBM-SPSS version 22.0.
Results
Forty-three MPS patients performed clinical and devel-
opmental tests, CSF and neuroimaging studies over 
3 years. The mean age of the patients was 13.7 years (age 
range 0.9–36 years). Severe forms of the disease (Hurler 
syndrome and severe form of MPS II) were observed in 
thirteen patients (30.2%). Macrocephaly (+2SD or 98%) 
was present in 32.6% of the patients. Based on IQ and 
development testing, 41.9% of the patients had cognitive 
impairment.
All the scores (Evans’ index, third ventricle width and 
callosal angle) used to assess the supratentorial ventricu-
lar enlargement in MPS patients presented a moderate 
correlation with the CSF aqueductal flow. Also, the ven-
tricular CSF volume correlated with the CSF aqueductal 
flow, which did not occur with the total CSF volume and 
the subarachnoid CSF volume (Table  1). The third ven-
tricle width showed a high inverse correlation with the 
brain volume  (rs = −0.61; p  <  0.001) and Evans’ index 
showed the highest correlation with the ventricular CSF 
volume  (rs = 0.87; p < 0.001). In addition, Evans and third 
ventricle width scores had large correlations  (rs =  0.64 
and  rs = 0.65, p < 0.001, respectively) with the total CSF 
volume. The other factor tested that correlated with the 
total CSF volume was the dilated PVS. The craniocervical 
junction stenosis significantly correlated with the cervical 
CSF flow  (rs = 0.46; p < 0.002) and was inversely corre-
lated with the subarachnoid CSF volume.
The CSF opening pressure did not correlate either with 
the three measures of ventriculomegaly or with the ven-
tricular CSF volume (Table  1). Also, no correlation was 
found between the CSF opening pressure and the CSF 
aqueductal flow  (rs = −0.23, p = 0.177), or the score for 
craniocervical stenosis  (rs = 0.19, p = 0.258). Table 1 also 
shows significant correlations between the dilated PVS 
and the WM lesion load with the ventricular CSF volume.
Table  2 shows the relationship between the clinical, 
CSF and neuroimaging features of MPS patients with 
ventriculomegaly and CSF flow. CSF GAG levels had no 
significant association with ventricle enlargement or CSF 
flow. The presence of ten or more dilated PVS showed 
significant association with ventriculomegaly, especially 
to the third ventricle width (Peto odds ratio 8.56, 95% CI 
2.23–32.88), and also with elevated CSF stroke volume at 
Fig. 2 CSF oscillations were reconstructed during the cardiac cycle at aqueductal level (a) and cervical level (b). Aqueductal CSF stroke volume and 
cervical CSF stroke volume represent the mean volume of CSF under the curve of CSF flow during the cardiac cycle
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the level of the cerebral aqueduct (Peto odds ratio 7.27, 
95% CI 1.72–30.74). The WM lesion severity was sig-
nificantly higher in patients with ventriculomegaly. The 
presence of craniocervical stenosis showed no significant 
association with decreased cervical CSF stroke volume. 
Representative cases are described in Figs. 3 and 4.
Discussion
One of the biggest challenges with MPS patients is to dis-
tinguish communicating hydrocephalus from ventricular 
dilatation secondary to brain atrophy. Although conven-
tional MRI sequences reveal morphological findings, 
when there is concern that developing hydrocephalus 
may require surgical management dedicated neuroim-
aging studies, including CSF flow measurement, may be 
indicated [15]. Ventricular dilation may be related to ven-
tricular wall modifications induced by an increase in the 
pressure gradient between ventricular CSF and extraven-
tricular CSF [32]. PC-MRI has the ability to measure 
ACSV, the elevation of which is associated with hydro-
cephalus. This is the first time that this technique has 
been described in MPS patients.
Evans’ index presented the highest correlation with 
ventricular CSF volumetrics and higher brain volume. 
Despite advances in brain imaging and volumetric 
analysis, this simple linear measurement continues to 
be fast, reliable and feasible for neurosurgical practice. 
The increased third ventricle width, which is a marker 
of brain atrophy in patients with multiple sclerosis [33, 
34], might also be a surrogate marker of brain atrophy 
in MPS patients. The third ventricle divides the thalamic 
hemispheres, and thalamic atrophy may give rise to ex 
vacuo enlargement of the third ventricle. The measure-
ment of the callosal angle, another supportive marker for 
the diagnosis of hydrocephalus and predictor of a posi-
tive outcome after shunting [35], presented good correla-
tion with the other scores and proved to be useful. For 
this reason, we recommend the assessment of ventricular 
size by these three indices, which may enhance the diag-
nostic accuracy of hydrocephalus in MPS patients [36].
Aqueductal CSF stroke volume was significantly corre-
lated with ventricular measurements and CSF ventricular 
volume. Chiang et al. demonstrated that the magnitude of 
ACSV is linked to the ventricular morphology [37], which 
is consistent with the finding by Poncelet et al. that the lat-
eral compressive motion of the thalami on the third ventri-
cle during the cardiac cycle modulates the CSF flow in the 
aqueduct [38]. Cerebrospinal fluid oscillations through the 
aqueduct appear to depend directly on CSF venting from 
the cranial cavity, resulting from both arterial inflow and 
the compliance of the craniospinal cavity [29]. In patients 
with communicating hydrocephalus, ventricular pulsa-
tions play a major role in cerebral pressure damping dur-
ing vascular brain expansion, and ventricular dilation 
seems to be an adaptive response to changes in suba-
rachnoid intracranial CSF pulsations [32]. With regard to 
patients with MPS, we believe that the obstruction of 
CSF reabsorption associated with cortical venous system 
hypertension due to impaired venous drainage caused by 
deformation of the skull base involve a reduction in the 
compliance of the subarachnoid space and limit total arte-
rial pulsation toward the ventricles, increasing the ACSV.
Fig. 3 Brain MRI scans of a 20-year-old male patient affected by MPS II (attenuated form). Axial FLAIR image a shows periventricular and subcortical 
(arrows) white matter lesions (lesion load = 1.8%). Axial T2-weighted image b shows dilated perivascular spaces (score 3) prominently seen in the 
thalami and basal ganglia (arrow) and enlargement of subarachnoid spaces. Midsagittal T2-weighted image c shows dilated perivascular spaces 
within the corpus callosum (arrowhead), and effacement of CSF (arrow) and spinal stenosis at C1–C2 (score 1)
Page 9 of 12Corte et al. Fluids Barriers CNS  (2017) 14:23 
The relationship between ventricle enlargement and 
decreased brain volume, and also the increased total CSF 
volume, which includes the CSF of subarachnoid spaces, 
might lead straight to the conclusion that ventriculo-
megaly is mainly due to cerebral atrophy. However, using 
the acquired knowledge from the patients with INPH 
who have also been found to have larger intracranial 
CSF volumes [39], it is more likely that, with decreased 
uptake of CSF by the arachnoidal granulations due to 
the deposition of storage material in the meninges, MPS 
patients might have developed a parallel pathway for 
CSF reabsorption, which could be the extracellular space 
of the brain. In accordance with this theory, we found a 
correlation between an increased number of dilated PVS 
with high CSF flow through the aqueduct, but also with 
larger total CSF volumes.
Cerebrospinal fluid opening pressure did not corre-
late with ventriculomegaly, CSF volume or CSF flow. In 
accordance with our results, the relationship between 
ICP, also considered as CSF opening pressure, and cere-
bral ventricle indices was shown as unreliable in pediatric 
and adult patients with communicating hydrocephalus 
Fig. 4 The three indices used for the assessment of ventricular size and the sagittal scout view sequences used for CSF flow quantifications at 
aqueductal level and C2–C3 level. a a 9-year-old girl with MPS I (Hurler syndrome): Evans’ index (EI) = 0.51. Width of III ventricle (WTV) = 19.4 mm. 
Callosal angle (CA) = 77.9°. CSF opening pressure (CSF OP) = 17.5 cm  H2O. Aqueductal CSF stroke volume (ACSV) = 0.04 ml/CC. Cervical CSF 
stroke volume (CCSV) = 0 ml/CC; b a 10-year-old boy with MPS II (severe form): EI = 0.42. WTV = 14.9 mm. CA = 52.8°. CSF OP = 40 cm  H2O. 
ACSV = 0.03 ml/CC. CCSV = 0.13 ml/CC; c a 8-year-old boy with MPS III A. EI = 0.43. WTV = 16.8 mm. Callosal angle = 50.7°. CSF opening pres-
sure = 17.5 cm  H2O. ACSV = 0.13 ml/CC. CCSV = 0.49 ml/CC
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and INPH [12–14]. Also, the assessment of changes in 
ventricular size gave no reliable prediction of changes 
in ICP [13]. The possible explanations are: (1) the devel-
opment of ventriculomegaly may require a longer time 
period as the arachnoid granulations fail to maintain 
their baseline removal of CSF, secondary to deposition 
of GAGs in subarachnoid spaces [40], which may initially 
result in elevation of the mean ICP, but as time elapses, 
assuming the PVS to serve as lymphatics of the brain, 
the CSF reabsorption may improve; (2) the compensa-
tory enlargement of cerebral ventricles and subarachnoid 
spaces in response to loss of brain tissue (hydrocephalus 
ex vacuo) in severe forms of MPS, may contribute to a 
reduction in ICP. In daily clinical practice changes in ven-
tricular size assessed by neuroimaging often are used as 
predictors of changes in ICP. In this context, short-term 
and long-term changes should be taken into account.
In MPS patients, the WM lesion severity is associated 
with ventriculomegaly. The loss of myelin, axons and 
oligodendoglial cells causes the environment to become 
more hydrophilic [41]. However minimal it might be, 
this is certain to increase the resistance to movement of 
free water through the extracellular space of the brain. 
Thus, there will be a tendency for CSF to back up in the 
ventricles, adding another mechanism to the impaired 
pathways of CSF egress from the ventricles to the suba-
rachnoid space [39]. Based on our results, ventriculo-
megaly is associated with a severe phenotype, increased 
cognitive decline and brain structural changes. Moreo-
ver, ventriculomegaly can be hypertensive or not. Thus, 
it is possible that atrophy, visualized as dilated cortical 
sulci and ventriculomegaly, may represent parenchy-
mal involvement of the disease and also may be a partial 
sequela of a form of communicating hydrocephalus [2].
This study provides new information for a better under-
standing of ventriculomegaly in MPS patients, including 
its relationship with the elevated aqueductal CSF flow. It 
also reinforces the importance of considering the amount 
of dilated PVS as a biomarker for the balance between 
production and CSF reabsorption. Moreover, our study 
describes a possible temporal correlation of the clinical 
and neuroimaging findings with some of the histopatho-
logical events in the brain of MPS patients. Lee et al. pro-
posed the natural course of cerebral involvement in MPS 
based on the MRI findings, and also postulated that cri-
briform changes occurred first, followed by WM changes 
and, last, atrophy [6]. Our study provides new data about 
the association of these changes with reabsorption failure 
of CSF in MPS patients. Besides that, we believe that the 
accumulation of CSF within the intracranial tissue is a 
major determinant of the clinical signs of hydrocephalus, 
more so than ventriculomegaly or elevated aqueductal 
CSF flow.
However, a weakness of the present study is the lack 
of correlation between ventriculomegaly and intra- and 
extracranial venous mean flow to test the hypothesis 
that venous hypertension due to reduced venous blood 
outflow may also play a role in the genesis of ventricu-
lar dilatation. Therefore, further studies are necessary 
to correlate cerebral venous blood flow with obstruc-
tion in cerebral veins, venous drainage anomalies, skull 
base abnormalities and communicating hydrocephalus 
in MPS patients. The T2 through-plane used for CSF 
volumetrics has low resolution. This is a technical limita-
tion of our study instead of using T1-MPRAGE sequence 
which could increase the sensitivity of volumetric meas-
urements comparison. Moreover, because ventricular 
size has limited specificity with regard to pathophysiol-
ogy of hydrocephalus, it is very likely that a stand-alone 
measurement of ACSV has poor specificity for differen-
tial diagnosis, as previously noted in INPH and in pre-
dicting the response to shunt surgery [23]. In addition, 
as ACSV is highly machine- and technique-dependent, it 
is recommended to first perform CSF flow studies on a 
number of healthy patients without dilated ventricles to 
determine what is normal on that scanner. Then, when 
a MPS patient with suspected hydrocephalus is evalu-
ated, a stroke volume at least twice that value would be 
required before recommending shunting [16]. Taking all 
of these factors together, it is our opinion that a combina-
tion of positive supplemental tests coupled with neuro-
logical deterioration can increase predictive accuracy in 
the diagnosis of hydrocephalus in MPS patients.
Conclusions
Brain ventricular size and ventricular CSF volume had 
significant association with ACSV in MPS patients. CSF 
opening pressure (ICP) had no association with any of 
the above measurements. It is possible that MPS patients 
are more heavily reliant on reabsorption via the extracel-
lular space of the brain. Perivascular spaces may repre-
sent the initial phase of abnormal CSF circulation, and 
ventriculomegaly may represent the later stages.
Although we have a better understanding of biomark-
ers associated with ventriculomegaly in MPS patients, 
these still do not provide a certain diagnosis for hydro-
cephalus or improve the accuracy of patient selection 
for surgical treatment. Concomitant analysis of venous 
and CSF flows using PC-MRI is necessary to search for 
impaired venous outflow and reduced intracranial com-
pliance due to jugular foramina narrowing and retro-
grade venous hypertension.
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